---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-25-000081"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2025-09-08T23:59:59+00:00"
generated_at: "2026-05-17T07:37:19.662419+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Keros reports KER-065 Phase 1 data: BMD improvements sustained to Day 141

## Summary
- Phase 1 trial in healthy males showed no dose-limiting toxicities or serious adverse events.
- Whole body BMD improved at Day 85 and was sustained through Day 141 (three months post-last dose).
- Lumbar spine BMD increased after three doses and remained elevated through Day 141.
- Bone biomarker changes indicated increased formation and reduced resorption, consistent with tissue-level effects.
- Data presented at ASBMR 2025 support potential in Duchenne muscular dystrophy and bone disorders.

## SEC filing metadata
- accession: 0001664710-25-000081
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2025-09-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000081/0001664710-25-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000081/kros-20250908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-25-000081
- JSON: https://secwatch.observer/filing/0001664710-25-000081.json
- Plain text: https://secwatch.observer/filing/0001664710-25-000081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.